The current status of hematopoietic stem cell transplantation for multiple myeloma.

WI Bensinger - Clinical Advances in Hematology & Oncology: H&O, 2004 - europepmc.org
Multiple myeloma is often successfully controlled with conventional chemotherapy, but
complete remissions are uncommon and cure is rare. High-dose therapy followed by …

[HTML][HTML] Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial

A Perrot, V Lauwers-Cances, T Cazaubiel, T Facon… - Blood, 2020 - Elsevier
Introduction The IFM 2009 study prospectively evaluated the combination of 8 cycles of
lenalidomide, bortezomib and dexamethasone (RVd) versus (vs) 3 cycles of RVd plus high …

[HTML][HTML] Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival

VH Jimenez-Zepeda, J Mikhael, A Winter… - Biology of Blood and …, 2012 - Elsevier
The role of a second autologous stem cell transplant (ASCT) as salvage therapy is unclear,
particularly with the availability of novel agents to treat progressive multiple myeloma (MM) …

Allogeneic hematopoietic cell transplantation for myeloma: when and in whom does it work

Q Bashir, MH Qazilbash - Current hematologic malignancy reports, 2017 - Springer
The growing list of available therapies for patients with multiple myeloma has resulted in
tremendously high response rates and prolonged survival. However, the cure remains …

Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center …

O Pasvolsky, S Ghanem, DR Milton, M Rauf… - Blood cancer …, 2024 - nature.com
The prognostic impact of additional copies of chromosome 1q (1q+) on outcomes of newly-
diagnosed multiple myeloma (NDMM) patients undergoing autologous transplantation …

[PDF][PDF] Long‐term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma

MC Vekemans, L Michaux… - British journal of …, 2014 - academia.edu
Despite the use of novel drugs and autologous stem cell transplantation (SCT), multiple
myeloma (MM) is still considered to be an incurable disease. Both autologous and …

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center

W Bensinger, M Rotta, B Storer, T Chauncey… - Bone marrow …, 2012 - nature.com
Allogeneic stem cell transplant for multiple myeloma (MM) is one treatment associated with
long-term disease-free survival. The high incidence of treatment-related mortality and …

[PDF][PDF] Predictive factors for early relapse in multiple myeloma after autologous hematopoietic stem cell transplant

AM Pourmoussa, R Spielberger… - The Permanente …, 2019 - thepermanentejournal.org
Introduction: Despite advances in therapy for multiple myeloma, patients have continued to
experience relapse. We sought to better understand this. Objective: To identify factors that …

[HTML][HTML] Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma

KKS Abbi, J Zheng, SM Devlin, S Giralt… - Biology of Blood and …, 2015 - Elsevier
Therapeutic options for patients with multiple myeloma (MM) whose disease has relapsed
after a prior autologous stem cell transplant (ASCT) include an expanding armamentarium of …

Stem-cell transplantation in multiple myeloma: how far have we come?

CY Soekojo, SK Kumar - Therapeutic advances in …, 2019 - journals.sagepub.com
High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) has historically
been an essential part of multiple myeloma (MM) management since early studies …